Neena Bitritto-Garg
Stock Analyst at Deutsche Bank
(2.79)
# 1,858
Out of 4,944 analysts
74
Total ratings
43.86%
Success rate
7.64%
Average return
Main Sectors:
Stocks Rated by Neena Bitritto-Garg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Initiates: Hold | $22 | $25.13 | -12.46% | 16 | Feb 11, 2025 | |
| ROIV Roivant Sciences | Maintains: Buy | $14 → $15 | $11.96 | +25.42% | 5 | Apr 3, 2024 | |
| AMLX Amylyx Pharmaceuticals | Maintains: Buy | $36 → $8 | $8.30 | -3.61% | 7 | Mar 11, 2024 | |
| IMVT Immunovant | Initiates: Buy | $50 | $15.89 | +214.66% | 1 | Dec 12, 2023 | |
| NBIX Neurocrine Biosciences | Initiates: Buy | $136 | $131.62 | +3.33% | 7 | Dec 12, 2023 | |
| CMPS COMPASS Pathways | Initiates: Buy | $16 | $4.29 | +272.96% | 4 | Dec 12, 2023 | |
| PRTA Prothena Corporation | Initiates: Buy | $62 | $8.05 | +670.19% | 8 | Dec 12, 2023 | |
| ALEC Alector | Initiates: Buy | $12 | $2.18 | +450.46% | 6 | Dec 12, 2023 | |
| SRPT Sarepta Therapeutics | Initiates: Buy | $109 | $20.40 | +434.31% | 3 | Dec 12, 2023 | |
| ABOS Acumen Pharmaceuticals | Initiates: Buy | $8 | $1.27 | +529.92% | 1 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $4.05 | +146.91% | 4 | Jan 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $6.38 | +1,467.40% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $6 | $8.62 | -30.39% | 5 | Aug 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $3.42 | +514.04% | 1 | Apr 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $23 | $122.87 | -81.28% | 1 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $36 | $20.74 | +73.62% | 2 | Jul 11, 2017 |
ACADIA Pharmaceuticals
Feb 11, 2025
Initiates: Hold
Price Target: $22
Current: $25.13
Upside: -12.46%
Roivant Sciences
Apr 3, 2024
Maintains: Buy
Price Target: $14 → $15
Current: $11.96
Upside: +25.42%
Amylyx Pharmaceuticals
Mar 11, 2024
Maintains: Buy
Price Target: $36 → $8
Current: $8.30
Upside: -3.61%
Immunovant
Dec 12, 2023
Initiates: Buy
Price Target: $50
Current: $15.89
Upside: +214.66%
Neurocrine Biosciences
Dec 12, 2023
Initiates: Buy
Price Target: $136
Current: $131.62
Upside: +3.33%
COMPASS Pathways
Dec 12, 2023
Initiates: Buy
Price Target: $16
Current: $4.29
Upside: +272.96%
Prothena Corporation
Dec 12, 2023
Initiates: Buy
Price Target: $62
Current: $8.05
Upside: +670.19%
Alector
Dec 12, 2023
Initiates: Buy
Price Target: $12
Current: $2.18
Upside: +450.46%
Sarepta Therapeutics
Dec 12, 2023
Initiates: Buy
Price Target: $109
Current: $20.40
Upside: +434.31%
Acumen Pharmaceuticals
Dec 12, 2023
Initiates: Buy
Price Target: $8
Current: $1.27
Upside: +529.92%
Jan 9, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $4.05
Upside: +146.91%
Nov 11, 2022
Maintains: Buy
Price Target: $140 → $100
Current: $6.38
Upside: +1,467.40%
Aug 2, 2022
Downgrades: Sell
Price Target: $6
Current: $8.62
Upside: -30.39%
Apr 4, 2022
Initiates: Buy
Price Target: $21
Current: $3.42
Upside: +514.04%
Jul 11, 2017
Initiates: Outperform
Price Target: $23
Current: $122.87
Upside: -81.28%
Jul 11, 2017
Initiates: Outperform
Price Target: $36
Current: $20.74
Upside: +73.62%